Why Novavax Stock More Than Doubled Today
Shares of Novavax (NASDAQ: NVAX) are up 12% as of midday Friday following the release of the drugmaker's first-quarter results. It's not the report, however, driving the bulk of today's oversize gain -- it's the announcement made in conjunction with it.
The company is partnering with fellow pharmaceutical company Sanofi (NASDAQ: SNY) to market Novavax's COVID vaccine. The deal also opens the door to the development of a flu vaccine based on Novavax's underlying science used to create its coronavirus jab.
For the quarter ending in March, Novavax had $94 million in revenue and a loss of $1.05 per share. These numbers are an improvement on the year-ago loss of $3.41 per share, on $81 million in sales.
Source Fool.com
Novavax Inc. Aktie
9,81 €
-6,96 %
Novavax Inc. ist ein kleiner Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Das Community-Kursziel von 22 € für Novavax Inc. zeigt eine potenzielle Verdopplung im Vergleich zum aktuellen Kurs von 9.81 €.
